Kisunla™ (donanemab-azbt) Referral Form

Preferred Clinic (select one):

Connecticut: 203-724-4838

Massachusetts: 781-202-1629

Florida: 904-930-4211

Minnesota: 763-290-0903

New Jersey: 609-955-3711

Nevada: 702-489-5744



PATIENT INFORMATION		New Referral	Updated Refer	rral Referral Renewal	
DOB: Patient Name:		Patient Phone: Patient Email:			
Patient Address:					
NKDA Allergies:		V	Veight (lbs/kg):	Height:	
CD-10 Code (required): ICD-10 Description:		reatment Date: Last 4 Digits SSN:		Digits SSN:	
PROVIDER INFORMATION					
Referral Coordinator Name:	Referra	al Coordinator Email:			
Ordering Provider:	Provid	Provider NPI:			
Referring Practice Name:	Phone	:	Fax:		
Practice Address:	City:		State:	Zip Code:	
Physician Preferred Method of Contact: Email:		Fax:	P	Phone:	
STANDING ORDERS ☑ Infusion to be administered per Vivo protocols.	KISUI	NLA ADMINISTRATIO	N	****MRIs should be	
LABORATORY ORDERS CBC w/ diff every CMP every OTHER		 Administer every 4 weeks: First dose: 350 mg IV Second dose: 700 mg IV Third dose: 1,050 mg IV 4th dose and beyond: 1, 			
PREMEDICATIONS (please write in):		1,400 mg IV ever			
DIAGNOSIS		Patient Demographics	:		
Mild Cognitive Impairment Due to Alzheimer's Disease – G31. Early Onset Alzheimer's Disease – G30.0 Late Onset Alzheimer's Disease – G30.1 Other Alzheimer's Disease – G30.8		Insurance Card/Inform	nation		
		Progress Notes Supporting DX Current Medication List and H&P			
		Cognitive Assessment Score (MMSE 20-28, CDR-GS 0.5 or 1) MRI Within 1 Year Confirmed presence of amyloid pathology			
					Alzheimer's Disease unspecified-G30.9
Medicare patients must be registered with CMS prior to the interest of the int		Advantage only) ApoE ε4 Testing (if available) Patient has been provided ARIA Risk counseling		unseling	
Provider Name (Print)	Provider Signature			Date	

Ohio: 216-400-0674

Oklahoma: 918-770-4421

Pennsylvania: 215-399-9244

Virginia: 804-500-5941

Wisconsin: 414-600-5383